Patient & Visitor InformationContact Us
  • Centers for Behavioral and Preventive Medicine

  • Kathleen Morrow, PhD  

    Kathleen Morrow, PhD
    Associate Professor
    The Miriam Hospital
    Centers for Behavioral and Preventive Medicine
    Coro West, Suite 309
    164 Summit Ave
    Providence, RI 02906
    Phone: 401-793-8010
    Fax: 401-793-8078  

  • Selected publications

  • (10 of over 40)

     Bentley, M., Morrow, K., Fullem, A., Chesney, M., Horton, S., Rosenberg, Z., & Mayer, K. (2000). Acceptability of a potential vaginal microbicide, BufferGel, during a phase I safety trial among low-risk women in Rhode Island. Family Planning Perspectives, 32(4), 184-188 (name changed to Perspectives on Sexual and Reproductive Health)]

    Morrow, K., Rosen, R., Richter, L., Emans, A., Forbes, A., Day, J., Morar, N., Maslankowski, L., Profy, A.T., Kelly, C., Abdool Karim, S., & Mayer, K. (2003). The acceptability of an investigational vaginal microbicide, PRO 2000 Gel in the context of a Phase I clinical trial. Journal of Women's Health, 12, 655-666.

    El-Sadr, W.M., Mayer, K.H., Maslankowski, L., Hoesley, C., Justman, J., Gai, F., Mauck, C., Absalon, J., Morrow, K., Mâsse, B., Soto-Torres, L. & Kwiecien, A. for the HIV Prevention Trials Network (HPTN) 049 Protocol Team. (2006). Safety and Acceptability of Cellulose Sulfate as a Vaginal Microbicide in HIV-infected Women. AIDS, 20, 1109-1116.

    Morrow, K.M., Fava, J.L., Rosen, R.K., Christensen, A.L., Vargas, S. & Barroso, C. (2007). Willingness to use microbicides varies by race/ethnicity, experience with prevention products, and partner type. Health Psychology, 26, 777-786.

    Morrow, K.M., Vargas, S., Rosen, R.K., Christensen, A.L., Salomon, L., Shulman, L., Barroso, C., Fava, J.L. (2007). The utility of non-proportional quota sampling for recruiting at-risk women for microbicide research. AIDS & Behavior, 11, 586-595.

    Morrow, K.M., Fava, J.L., Rosen, R.K., Vargas, S., Barroso, C., Christensen, A.L., Woodsong, C., Severy, L. (2007). Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties. Journal of Acquired Immune Deficiency Syndromes, 45, 93-101.

    Rosen, R., Morrow, K., Carballo-Diéguez, A., Mantell, J., Hoffman, S, Gai, F., Maslankowski, L., El-Sadr, W., & Mayer, K. (2008). Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. Journal of Women's Health, 17, 383-392.

    Morrow,K.M., &. Ruiz, M.S. (2008). Assessing Microbicide Acceptability: A Comprehensive and Integrated Approach. AIDS & Behavior, 12(2), 272-283.

    Tolley, E.E., Harrison, P.F., Goetghebeur, E. Morrow, K., Pool, R, Taylor, D, Tillman, S.N., & van der Straten, A. (epub ahead of print; 2009). Adherence and its measurement in Phase 2/3 microbicide trials. AIDS & Behavior.

    Buckheit, R.W., Watson, K.M., Morrow, K.M., Ham, A.S. (2010). Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Research, 85, 142-158.